The NGAL TestTM
When it comes to acute kidney injury…
Know earlier. Manage better. With confidence.
Intended Use: The NGAL Test™ is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma and heparin plasma on automated clinical chemistry analyzers. NGAL measurements are useful in the diagnosis of acute kidney injury (AKI) which may lead to acute renal failure.
*CE-Marked for IVD use in the European Union.
The NGAL Test™
Identifying Acute Kidney Injury (AKI) early is difficult because the current standard of care relies on changes in serum creatinine and urine output, physiologic endpoints that are delayed, non-specific, and impacted by extrarenal factors such as nutrition status and muscle mass.i
The NGAL Test quantifies levels of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA and heparin plasma. A damage biomarker that rises rapidly in response to kidney injury, NGAL precedes changes in creatinine by as much as 2 to 3 days.ii
By integrating a damage marker into their clinical assessment, clinicians can identify AKI early and confidently take action to manage fluid levels, avoid nephrotoxic agents, and potentially prevent permanent kidney damage.iii
Ready to Get Started?
While each hospital has its own method for adding new lab tests into clinical practice, several steps are common and BioPorto is available to ease and expedite the process. From initial exploratory meetings and clinical education to economic justifications and lab validation, the BioPorto team has experience helping customers onboard this important assay.
GET HELP FROM THE TEAM
i Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med. 2010;4(2):265–280.
ii Krawczeski CD, Goldstein SL, Woo JG, et al. Temporal relationship and predictive value of urinary acute kidney injury biomarkers after pediatric cardiopulmonary bypass. J Am Coll Cardiol. 2011;58(22):2301–2309.
iii Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020;3(10):e2019209.